(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,641.63%.
Cocrystal Pharma's earnings in 2026 is -$8,831,000.On average, 5 Wall Street analysts forecast COCP's earnings for 2026 to be -$11,108,565, with the lowest COCP earnings forecast at -$13,104,743, and the highest COCP earnings forecast at -$8,829,779.
In 2027, COCP is forecast to generate -$13,639,630 in earnings, with the lowest earnings forecast at -$13,104,743 and the highest earnings forecast at -$14,040,796.